| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/02/2009 | CA2710791A1 Pyripyropene derivatives having an acat2-inhibiting activity |
| 07/02/2009 | CA2710646A1 Medicament for the treatment of cancer of the pancreas |
| 07/02/2009 | CA2710644A1 Macrocyclic indoles as hepatitis c virus inhibitors |
| 07/02/2009 | CA2710605A1 Anti - retroviral combination |
| 07/02/2009 | CA2710441A1 Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| 07/02/2009 | CA2710345A1 Triazole oxadiazoles derivatives |
| 07/02/2009 | CA2710335A1 Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists |
| 07/02/2009 | CA2710293A1 Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
| 07/02/2009 | CA2710171A1 The use of 6-halogeno-[1,2,4]-triazolo-[1,5-a]-pyrimidine compounds for combating pests in and on animals |
| 07/02/2009 | CA2710152A1 Processes to pregabalin |
| 07/02/2009 | CA2710151A1 Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9h-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as a2ar agonists |
| 07/02/2009 | CA2710144A1 Hcv protease inhibitors and uses thereof |
| 07/02/2009 | CA2710130A1 Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
| 07/02/2009 | CA2710125A1 Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubility |
| 07/02/2009 | CA2710123A1 Polysaccharide derivatives of lipoic acid, their preparation, use as skin cosmetics and medical devices |
| 07/02/2009 | CA2710122A1 Thiazole derivatives used as pi 3 kinase inhibitors |
| 07/02/2009 | CA2710118A1 Sulfamides as zap-70 inhibitors |
| 07/02/2009 | CA2710116A1 Preparations with rosehip extracts, and method of producing rosehip extracts |
| 07/02/2009 | CA2710087A1 Antitumoral compounds |
| 07/02/2009 | CA2710067A1 Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
| 07/02/2009 | CA2710055A1 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases |
| 07/02/2009 | CA2710039A1 Compounds and method for treatment of cancer |
| 07/02/2009 | CA2710016A1 Translocator protein ligands |
| 07/02/2009 | CA2709937A1 Halogenated analogues of anti-fibrotic agents |
| 07/02/2009 | CA2709913A1 Method of stimulating the motility of the gastrointestinal system using ipamorelin |
| 07/02/2009 | CA2709909A1 Pharmaceutical composition |
| 07/02/2009 | CA2709861A1 Pharmaceutical compositions |
| 07/02/2009 | CA2709727A1 Pharmaceutical composition for improving lower urinary tract symptoms |
| 07/02/2009 | CA2709677A1 Selective androgen receptor modulators (sarms) and uses thereof |
| 07/02/2009 | CA2709664A1 Method for manufacturing heterocycle substituted pyridine derivatives |
| 07/02/2009 | CA2709650A1 4-amino-pyrimidine derivatives |
| 07/02/2009 | CA2709635A1 Polypeptide-nucleic acid conjugates and uses thereof |
| 07/02/2009 | CA2709538A1 Pharmaceutical formulations containing tolperisone |
| 07/02/2009 | CA2709536A1 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer |
| 07/02/2009 | CA2709535A1 Hcv protease inhibitors and uses thereof |
| 07/02/2009 | CA2709530A1 Monosebacate of pyrazole derivative |
| 07/02/2009 | CA2709514A1 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| 07/02/2009 | CA2709510A1 Bis-(sulfonylamino) derivatives for use in therapy |
| 07/02/2009 | CA2709348A1 Heterocyclic antiviral compounds |
| 07/02/2009 | CA2709343A1 Compositions and methods for supporting heat shock protein function |
| 07/02/2009 | CA2709199A1 Pre-surgical treatment |
| 07/02/2009 | CA2709169A1 Pyridazine derivatives useful as fungicides and for the treatment of cancer |
| 07/02/2009 | CA2708764A1 Induced viscosity nutritional emulsions comprising a carbohydrate-surfactant complex |
| 07/02/2009 | CA2708686A1 Methods of inhibiting tumor growth using ttk antagonists |
| 07/02/2009 | CA2708512A1 Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease |
| 07/02/2009 | CA2708502A1 Perhydroquinoxaline derivatives |
| 07/02/2009 | CA2708447A1 Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition |
| 07/02/2009 | CA2708372A1 Carboxyl- or hydroxylsubstituted benzimidazole derivatives |
| 07/02/2009 | CA2708312A1 Spiroindolinone derivatives as anticancer agents |
| 07/02/2009 | CA2708176A1 Azaindolizines and methods of use |
| 07/02/2009 | CA2707660A1 Carbamoyl compounds as dgat1 inhibitors 190 |
| 07/02/2009 | CA2707650A1 Substituted hydantoins as mek kinase inhibitors |
| 07/02/2009 | CA2707646A1 Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders |
| 07/02/2009 | CA2707618A1 Steroid derivatives acting as glucocorticosteroid receptor agonists |
| 07/02/2009 | CA2707447A1 Sulfonyl-substituted 6-membered ring derivative |
| 07/02/2009 | CA2707403A1 N-pyrazole-2-pyridinecarboxamide derivative |
| 07/02/2009 | CA2707333A1 Crystalline form of azelastine |
| 07/02/2009 | CA2706372A1 Crystalline polymorph of doxazosin mesylate (form iv) and process for preparation thereof |
| 07/02/2009 | CA2705411A1 Heteroaryl derivatives as orexin receptor antagonists |
| 07/02/2009 | CA2704268A1 Receptor targeting ligands |
| 07/01/2009 | EP2075346A2 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/01/2009 | EP2075341A1 Method for study, determination or evaluation by gene expression analysis |
| 07/01/2009 | EP2075334A1 EG-VEGF nucleic acids and polypeptides and methods of use |
| 07/01/2009 | EP2075333A1 Positive controls for expression modulating experiments |
| 07/01/2009 | EP2075255A1 Human FGF-23 gene and gene expression products |
| 07/01/2009 | EP2075254A1 Therapeutic use of a growth factor, NsG33 |
| 07/01/2009 | EP2075252A1 Nk1 receptor antagonist composition |
| 07/01/2009 | EP2075250A2 Thrombin receptor antagonists |
| 07/01/2009 | EP2075249A2 Indolylmaleimide derivatives |
| 07/01/2009 | EP2075246A1 A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| 07/01/2009 | EP2075031A1 Methods and systems for enhancing fluid flow trough an obstructed vascular site |
| 07/01/2009 | EP2075010A1 Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof |
| 07/01/2009 | EP2075001A1 Pharmaceutical combinations for the treatment of dyslipidemia accompanied by high blood pressure |
| 07/01/2009 | EP2075000A1 Combination of azelastine and ciclesonide |
| 07/01/2009 | EP2074999A1 Use of rubescensine a and derivatives thereof in pharmacy |
| 07/01/2009 | EP2074998A2 Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems |
| 07/01/2009 | EP2074997A1 Use of Asimadoline for the treatment of digestive disorders |
| 07/01/2009 | EP2074996A1 Synergistic compositions with analgesic properties comprising n-acylated 4-hydroxyphenylamine derivatives |
| 07/01/2009 | EP2074995A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| 07/01/2009 | EP2074994A1 Enhanced ocular neuroprotection/neurostimulation |
| 07/01/2009 | EP2074993A1 Venlafaxine-containing film-coated modified-release tablets |
| 07/01/2009 | EP2074992A1 Pharmaceutical formulations |
| 07/01/2009 | EP2074990A1 Controlled release flurbiprofen and muscle relaxant combinations |
| 07/01/2009 | EP2074989A1 Abuse resistance opioid transdermal delivery device |
| 07/01/2009 | EP2074985A2 Activator including biosurfactant as active ingredient, mannosyl erythritol lipid, and production method thereof |
| 07/01/2009 | EP2074889A1 Animal feed additive and animal feed |
| 07/01/2009 | EP2074221A2 Improved methods for the separation of streptococcus pneumoniae type 3 polysaccharides |
| 07/01/2009 | EP2074135A2 Silicon derivatives for pet imaging |
| 07/01/2009 | EP2074131A2 Anticoagulant compounds |
| 07/01/2009 | EP2074130A1 Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| 07/01/2009 | EP2074128A1 Therapeutic pyrazolyl thienopyridines |
| 07/01/2009 | EP2074127A1 Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
| 07/01/2009 | EP2074125A1 Phenylacetamides useful as protein kinase inhibitors |
| 07/01/2009 | EP2074124A1 3- (benzo [d][1,3]dioxol-5-ylmethyl) -4- (thio) oxo-2- (thio) oxo-azolidin-5-ylidene derivatives as antibacterial agents |
| 07/01/2009 | EP2074123A1 Novel anxiolytic compounds |
| 07/01/2009 | EP2074122A1 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| 07/01/2009 | EP2074121A1 Chymase inhibitors |
| 07/01/2009 | EP2074120A1 Tropane compounds |
| 07/01/2009 | EP2074119A1 Indole compound |
| 07/01/2009 | EP2074118A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |